Skip to main content
Top
Published in: Annals of Surgical Oncology 4/2015

01-04-2015 | Endocrine Tumors

Clinical and Socioeconomic Factors Influence Treatment Decisions in Graves’ Disease

Authors: Dawn M. Elfenbein, MD, MPH, David F. Schneider, MD, MS, Jeffrey Havlena, MS, Herbert Chen, MD, Rebecca S. Sippel, MD

Published in: Annals of Surgical Oncology | Issue 4/2015

Login to get access

Abstract

Background

Definitive treatment of Graves’ disease includes radioactive iodine (RAI) and thyroidectomy, but utilization varies. We hypothesize that, in addition to clinical reasons, there are socioeconomic factors that influence whether a patient undergoes thyroidectomy or RAI.

Methods

Patients treated for Graves’ disease between August 2007 and September 2013 at our university hospital were included. A comparative analysis of clinical and socioeconomic factors was completed.

Results

Of 427 patients, 300 (70 %) underwent RAI, whereas 127 (30 %) underwent surgery. Multiple factors were associated with surgery: younger age (mean 36 vs. 41 years, p < 0.01), female gender (33 vs. 19 % males, p = 0.01), black race (56 vs. 28 % nonblack, p < 0.01), Medicaid or uninsured (43 vs. 27 % private insurance or Medicare, p < 0.01), ophthalmopathy (38 vs. 26 %, p < 0.01), goiter (35 vs. 23 %, p < 0.01), and lowest quartile of median household income (38 vs. 27 % upper three quartiles, p = 0.03). Thyroidectomy increased annually, with 52 % undergoing surgery during the final year (p < 0.01). Adjusting for confounding, younger age (odds ratio [OR] 1.04; 95 % confidence interval [CI] 1.02, 1.05), female gender (OR 2.06; 95 % CI 1.06, 4.01), ophthalmopathy (OR 2.35; 95 % CI 1.40, 3.96), and later year of treatment (OR 1.66; 95 % CI 1.41, 1.95) remained significantly associated with surgery.

Conclusions

Surgery has now become the primary treatment modality of choice for Graves’ disease at our institution. Clinical factors are the main drivers behind treatment choice, but patients with lower SES are more likely to have clinical features best treated with surgery, underlying the importance of improving access to quality surgical care for all patients.
Literature
2.
go back to reference Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract. 2011;17(3):456–520.CrossRefPubMed Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract. 2011;17(3):456–520.CrossRefPubMed
3.
go back to reference Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97(12):4549–58.CrossRefPubMed Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97(12):4549–58.CrossRefPubMed
4.
go back to reference Liu J, Bargren A, Schaefer S, Chen H, Sippel RS. Total thyroidectomy: a safe and effective treatment for Graves’ disease. J Surg Res. 2011;168(1):1–4.CrossRefPubMedCentralPubMed Liu J, Bargren A, Schaefer S, Chen H, Sippel RS. Total thyroidectomy: a safe and effective treatment for Graves’ disease. J Surg Res. 2011;168(1):1–4.CrossRefPubMedCentralPubMed
5.
go back to reference Yip J, Lang BH, Lo CY. Changing trend in surgical indication and management for Graves’ disease. Am J Surg. 2012;203(2):162–7.CrossRefPubMed Yip J, Lang BH, Lo CY. Changing trend in surgical indication and management for Graves’ disease. Am J Surg. 2012;203(2):162–7.CrossRefPubMed
6.
go back to reference Snyder S, Govednik C, Lairmore T, Jiang DS, Song J. Total thyroidectomy as primary definitive treatment for Graves’ hyperthyroidism. Am Surg. 2013;79(12):1283–8.PubMed Snyder S, Govednik C, Lairmore T, Jiang DS, Song J. Total thyroidectomy as primary definitive treatment for Graves’ hyperthyroidism. Am Surg. 2013;79(12):1283–8.PubMed
7.
go back to reference Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, et al. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013;98(9):3671–7.CrossRefPubMedCentralPubMed Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, et al. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013;98(9):3671–7.CrossRefPubMedCentralPubMed
8.
go back to reference Stalberg P, Svensson A, Hessman O, Akerstrom G, Hellman P. Surgical treatment of Graves’ disease: evidence-based approach. World J Surg. 2008;32(7):1269–77.CrossRefPubMed Stalberg P, Svensson A, Hessman O, Akerstrom G, Hellman P. Surgical treatment of Graves’ disease: evidence-based approach. World J Surg. 2008;32(7):1269–77.CrossRefPubMed
9.
go back to reference Schneider DF, Sonderman PE, Jones MF, Ojomo KA, Chen H, Jaume JC, et al. Failure of radioactive iodine in the treatment of hyperthyroidism. Ann Surg Oncol. 2014. doi:10.1245/s10434-014-3858-4. Schneider DF, Sonderman PE, Jones MF, Ojomo KA, Chen H, Jaume JC, et al. Failure of radioactive iodine in the treatment of hyperthyroidism. Ann Surg Oncol. 2014. doi:10.​1245/​s10434-014-3858-4.
10.
go back to reference Jin J, Sandoval V, Lawless ME, Sehgal AR, McHenry CR. Disparity in the management of Graves’ disease observed at an urban county hospital: a decade-long experience. Am J Surg. 2012;204(2):199–202.CrossRefPubMedCentralPubMed Jin J, Sandoval V, Lawless ME, Sehgal AR, McHenry CR. Disparity in the management of Graves’ disease observed at an urban county hospital: a decade-long experience. Am J Surg. 2012;204(2):199–202.CrossRefPubMedCentralPubMed
11.
go back to reference Kandil E, Noureldine SI, Abbas A, Tufano RP. The impact of surgical volume on patient outcomes following thyroid surgery. Surgery. 2013;154(6):1346–52; discussion 1352–3.CrossRefPubMed Kandil E, Noureldine SI, Abbas A, Tufano RP. The impact of surgical volume on patient outcomes following thyroid surgery. Surgery. 2013;154(6):1346–52; discussion 1352–3.CrossRefPubMed
12.
go back to reference Wang TS, Sippel RS. Expansion of endocrine surgery fellowships: if we increase the supply is there demand? Surgery. 2013;154(6):1470–2.CrossRefPubMed Wang TS, Sippel RS. Expansion of endocrine surgery fellowships: if we increase the supply is there demand? Surgery. 2013;154(6):1470–2.CrossRefPubMed
13.
go back to reference Noureldine SI, Abbas A, Tufano RP, Srivastav S, Slakey DP, Friedlander P, et al. The impact of surgical volume on racial disparity in thyroid and parathyroid surgery. Ann Surg Oncol. 2014;21(8):2733–9. doi:10.1245/s10434-014-3610-0. Noureldine SI, Abbas A, Tufano RP, Srivastav S, Slakey DP, Friedlander P, et al. The impact of surgical volume on racial disparity in thyroid and parathyroid surgery. Ann Surg Oncol. 2014;21(8):2733–9. doi:10.​1245/​s10434-014-3610-0.
Metadata
Title
Clinical and Socioeconomic Factors Influence Treatment Decisions in Graves’ Disease
Authors
Dawn M. Elfenbein, MD, MPH
David F. Schneider, MD, MS
Jeffrey Havlena, MS
Herbert Chen, MD
Rebecca S. Sippel, MD
Publication date
01-04-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 4/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4095-6

Other articles of this Issue 4/2015

Annals of Surgical Oncology 4/2015 Go to the issue